Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Vor Biopharma ( (VOR) ) is now available.
On July 17, 2025, Vor Biopharma announced significant leadership changes, including the resignation of board member Sven (Bill) Ante Lundberg and the appointment of Qing Zuraw as Chief Development Officer. Dr. Zuraw brings over 25 years of experience in clinical development, having previously led successful trials for autoimmune diseases at RemeGen Co., Ltd. Additionally, the company expanded its board by appointing Michel Detheux and Alexander Cumbo as independent directors, enhancing its strategic leadership as it focuses on advancing its autoimmune therapeutic programs.
The most recent analyst rating on (VOR) stock is a Hold with a $0.40 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.
Spark’s Take on VOR Stock
According to Spark, TipRanks’ AI Analyst, VOR is a Underperform.
Vor Biopharma faces significant financial challenges, with no revenue and ongoing losses. Technical indicators suggest weak market sentiment, and the lack of positive valuation metrics further underscores the risk. Investors should be cautious due to the high financial risk and uncertainty.
To see Spark’s full report on VOR stock, click here.
More about Vor Biopharma
Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases. The company is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide.
Average Trading Volume: 17,861,349
Technical Sentiment Signal: Buy
Current Market Cap: $276.2M
See more insights into VOR stock on TipRanks’ Stock Analysis page.